

**NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE**

**Proposed Single Technology Appraisal**

**Ivabradine for the treatment of chronic heart failure**

**Provisional matrix of consultees and commentators (pre-referral)**

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• Servier Laboratories (ivabradine)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action Heart</li> <li>• Afiya Trust</li> <li>• Black Health Agency</li> <li>• British Cardiac Patients Association</li> <li>• Cardiomyopathy Association</li> <li>• Chinese National Healthy Living Centre</li> <li>• Counsel and Care</li> <li>• Equalities National Council</li> <li>• Heart Care Partnership (UK)</li> <li>• Muslim Council of Britain</li> <li>• Muslim Health Network</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• British Association for Nursing in Cardiac Care</li> <li>• British Association for Service to the Elderly</li> <li>• British Cardiovascular Intervention Society (BCIS)</li> <li>• British Cardiovascular Society</li> <li>• British Geriatrics Society</li> <li>• British Heart Foundation</li> <li>• British Society for Heart Failure</li> <li>• National Heart Forum (UK)</li> <li>• National Pharmacy Association</li> <li>• Primary Care Cardiovascular Society</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Board of Community Health Councils in Wales</li> <li>• British Cardiovascular Industry Association</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Commissioning Support Appraisals Service</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Health Care Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Public Health Wales NHS Trust</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Possible comparator manufacturers</u></p> <ul style="list-style-type: none"> <li>• AAH Pharmaceuticals (spiro lactone, hydralazine, isosorbide dinitrate)</li> <li>• Abbott Healthcare Products (eprosartan)</li> <li>• Actavis UK (spironolactone, losartan, hydralazine, isosorbide dinitrate)</li> <li>• Almus Pharmaceuticals (spironolactone)</li> <li>• Arrow Generics (losartan)</li> <li>• Boehringer Ingelheim (telmisartan)</li> <li>• Bristol-Myers Squibb (irbesartan)</li> <li>• Consilient Health (losartan)</li> <li>• Daiichi Sankyo UK (olmesartan)</li> </ul>

## Appendix C

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<ul style="list-style-type: none"> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Society of Medicine</li> <li>• Society for Cardiological Science &amp; Technology</li> <li>• United Kingdom Clinical Pharmacy Association</li> <li>• Vascular Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS Central and Eastern Cheshire</li> <li>• NHS Devon</li> <li>• Welsh Assembly Government</li> </ul>	<p>medoxomil)</p> <ul style="list-style-type: none"> <li>• Dexcel Pharma (losartan)</li> <li>• Dr Reddy's Laboratories (spironolactone, losartan)</li> <li>• Essential Generics (isosorbide dinitrate)</li> <li>• Goldshield Critical Care (isosorbide dinitrate)</li> <li>• Kent Pharmaceuticals (spironolactone, losartan)</li> <li>• Lupin Europe (losartan)</li> <li>• Merck Sharp &amp; Dohme (losartan)</li> <li>• Metwest Pharmaceuticals (spironolactone)</li> <li>• Mylan (losartan, hydralazine)</li> <li>• Novartis Pharmaceuticals (valsartan)</li> <li>• Pfizer (losartan, eplerenone, spironolactone)</li> <li>• Ratiopharm UK (losartan)</li> <li>• Sandoz UK (losartan)</li> <li>• Sanofi-aventis (spironolactone, irbesartan)</li> <li>• Sovereign Medical (losartan, hydralazine)</li> <li>• Takeda UK (candesartan cilexetil)</li> <li>• Teva UK (spironolactone, losartan)</li> <li>• UCB Pharma (isosorbide dinitrate)</li> <li>• Winthrop Pharmaceuticals (losartan)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• British Society for Cardiovascular Research [BCS affiliated]</li> <li>• Cardiovascular Diseases Specialist Library (CVDSL)</li> <li>• Central Cardiac Audit Database</li> <li>• Cochrane Heart Group</li> <li>• MRC Clinical Trials Unit</li> <li>• National Heart Research Fund</li> <li>• National Institute for Health Research</li> <li>• Research Institute for the Care of Older People</li> <li>• Wellcome Trust - Cardiovascular Research Initiative</li> </ul>

## Appendix C

Consultees	Commentators (no right to submit or appeal)
	<p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> <li>• Evidence Review Group tbc</li> <li>• National Institute for Health Research Health Technology Assessment Programme</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• National Clinical Guidelines Centre</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• tbc</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do share it. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

### **Definitions:**

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland ; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

#### Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

---

<sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.